Additional mutations are found in 40 to 95% of AML with somatic mutation of RUNX1, especially in splicing and epigenetic factors (SRSF2, SF3B1, ASXL1, IDH1/IDH2, TET2, BCOR, MLL-PTD, and DNMT3A), with sub-clonal mutations in signaling pathways (FLT3, NRAS) [108,110,111]. Here, FLT3 is linked to acute myeloid leukemia.